Doctor and patient

History

Sareum was founded in August 2003 as a spin out from Millennium Pharmaceuticals' Structure-Based Discovery Department. Following an initial private investment, the company was successfully admitted to the Alternative Investment Market (AIM) of the London Stock Exchange in October 2004.

Since 2008, the company has focused on developing its drug discovery programmes operating with an outsourced and collaborative business model.

Find out more about how we work.

  • @Sareumplc Latest tweet

    Roche's discontinuation of its CHK1 inhibitor, RG7741 (aka Genentech's GDC-0575), means this mechanism is now a two… https://t.co/xq9zzVT44p via @Sareumplc
    View more